Low-Dose IL-2 and IL-12 Secretion in Metastatic Cancer Patients
Author Information
Author(s): P Lissoni, L Fumagalli, F Rovel, F Briviol, G Di Felice, F Majorca
Primary Institution: San Gerardo Hospital, Monza, Milan, Italy
Hypothesis
Does subcutaneous low-dose IL-2 stimulate IL-12 secretion in metastatic cancer patients?
Conclusion
Low-dose IL-2 immunotherapy may stimulate the in vivo release of IL-12, which is associated with a favorable prognosis.
Supporting Evidence
- IL-2 injection significantly increased IL-12 levels in patients with stable disease or response.
- Patients with high pretreatment IL-12 levels had a higher rate of disease progression.
- 10 out of 12 patients with response or stable disease showed an increase in IL-12 levels greater than 50%.
Takeaway
This study found that giving a small dose of a treatment called IL-2 can help the body produce a substance called IL-12, which might help fight cancer better.
Methodology
The study involved 19 metastatic renal cell cancer patients receiving low-dose IL-2, with serum IL-12 levels measured before and during treatment.
Limitations
The study had a small sample size and only included one type of cancer.
Participant Demographics
20 metastatic renal cell cancer patients (14 males, 6 females; median age 61 years).
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website